THE IMPACT OF REFORMULATED OXYCONTIN® IN AUSTRALIA: KEY FINDINGS FROM THE NATIONAL OPIOID MEDICATIONS ABUSE DETERRENCE (NOMAD)

B Larance¹, R Ali², M Farrell¹, A Peacock¹, R Bruno³, N Lintzeris⁴,⁵, T Dobbins¹, L Degenhardt¹

¹National Drug and Alcohol Research Centre, UNSW Australia, Sydney, New South Wales, Australia
²University of Adelaide, Adelaide, South Australia, Australia
³University of Tasmania, Hobart, Tasmania, Australia
⁴Discipline of Addiction Medicine, Central Clinical School, University of Sydney, Sydney, Australia
⁵Drug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, Australia

Introduction and Aims: Pharmaceutical companies are investing in developing opioid formulations less prone to extra-medical use and diversion. In Australia, a potentially tamper-resistant formulation of OxyContin® (Reformulated OxyContin®) was introduced in April 2014, followed by a generic brand of (non-tamper-resistant) oxycodone (Oxycodone Sandoz®) later the same year. The National Opioid Medications Abuse Deterrence (NOMAD) study examined the impacts of these two opioid formulations.

Design and Methods: The NOMAD study components include (1) routine data sources (e.g., opioid sales and Needle-Syringe Program (NSP) data); (2) Illicit Drug Reporting System (IDRS) data; and (3) a prospective cohort of 600 people who regularly tamper with pharmaceutical opioids. The NOMAD cohort was recruited and interviewed just prior to the introduction of Reformulated OxyContin®, and followed up at 3 and 12 months post-reformulation.

Results: Prior to reformulation, 80mg OxyContin® were most frequently diverted/injected in the NOMAD cohort. Post-reformulation, there were declines in OxyContin®/oxycodone use and injection in NOMAD cohort and NSP/IDRS data. Oxycodone Sandoz® injection was low in the NOMAD cohort (5%). There was no increase in other substance use or harms in the NOMAD cohort, consistent with available NSP data. Some tampering with Reformulated OxyContin® persisted at 12 months (27% past month attempts). Overall, Reformulated OxyContin® was viewed as less attractive for tampering/injection.

Discussion and Conclusions: These are the most detailed data on extra-medical pharmaceutical opioid use and tampering ever collected in Australia. Abuse-deterrent formulations may play a role in reducing the risks of pharmaceutical opioids, but no single intervention can address every aspect of pharmaceutical opioid use and harm.